<DOC>
	<DOCNO>NCT03046251</DOCNO>
	<brief_summary>The purpose study evaluate monthly natalizumab , initiate delivery , effective prevent postpartum relapse .</brief_summary>
	<brief_title>Natalizumab Preventing Post-partum Relapses Multiple Sclerosis</brief_title>
	<detailed_description>Postpartum patient diagnosis multiple sclerosis ( MS ) give opportunity enroll study evaluate efficacy IV natalizumab prevent postpartum relapse . Natalizumab , administer 300mg IV q 4 week , initiate postpartum ( 0-30 day post-delivery ) . Patients decline natalizumab treatment postpartum give opportunity enroll study control group . The control group similar inclusion exclusion criterion well schedule visit study procedure active natalizumab treatment group . The primary objective trial ass efficacy IV administer natalizumab , monthly 1 year , prevent relapse postpartum period . The secondary objective trial ass efficacy natalizumab decrease risk disability progression postpartum period prevent appearance new and/or enlarge brain MRI lesion measure qualitative MRI analysis . The tertiary objective ass association clinical outcome subject evaluation include patient report outcome .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>1 . Female subject postpartum , 030 day postpartum time inform consent . 2 . Diagnosis relapse form MS. 3 . Willing initiate natalizumab enroll TOUCH system . 4 . Willing able comply study procedure duration trial . 5 . Signed informed consent HIPAA authorization . 1 . Diagnosis primary progressive MS. 2 . Breastfeeding 3 . Use IVIG Tysabri treat subject . 4 . Significant renal hepatic impairment ( opinion investigator ) significant disease ( e.g. , cognitive impairment ) would compromise adherence completion trial . 5 . History hypersensitivity previous exposure presence antibody natalizumab . 6 . Any factor , opinion investigator , would make subject unsuitable participation study . 7 . Patients experience relapse and/or initiate DMT 's pregnancy The Control group consist relapse MS patient postdelivery decline natalizumab therapy open enroll study . Similar Inclusion Exclusion criterion natalizumab group exception require TOUCH enrollment program . The Control group allow initiate FDA approve DMT time post delivery remain therapy breastfeeding .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>